Marksans Pharma on Tuesday said that UK MHRA has granted marketing authorisation to its wholly-owned subsidiary, Relonchem Ltd, UK, for loratadine 5mg/5ml oral solution. The product will be manufactured in its UK facility. Loratadine oral solution is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. Shares of Marksans Pharma declined 2.2 per cent at ₹24.35 on the NSE.
Company news: Marksans Pharma
Published on
February 5, 2019 17:05